title: Counterpoint: Standard vs Investigational Agents as Upfront Treatment for High-Risk AML.
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Brunner
authors.forename: Wendy
authors.initials: W
authors.lastname: Stock
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D055808:Drug Discovery; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D058990:Molecular Targeted Therapy; D012074:Remission Induction; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015507:Drugs, Investigational